Our data suggest that the tumor-selective activity of this combination therapy arises from the presence of oncogenic Ras/Raf mutations in cancer cells, which drive constitutive activation of MEK signaling, and tumor cells with Ras/Raf mutations exhibit autocrine activation of the LIF/LIFR pathway, further sensitizing them to EC359. This evidence concerns the gene LIF and neoplasm.